COVID-19 therapies: The EU strikes back

More than six months after a novel coronavirus in China first hit headlines, we’re staggering under the scope of the pandemic. How much energy and how many resources should we be pumping into vaccines, mass diagnostic testing or new therapeutics? Europe is making plans to bring production of some medicines back from Asia. Just one step in a strategy that could prove perfect or pointless, in a world that is continuing to batten down the hatches. We look at some of the many measures that could make a difference. In this issue:

• European Greens fight over 'new genetic engineering' and a revision of the EU's GMO law
• Antimicrobial Resistance is back on the global agenda
• Industrial Biotechnology – achieving a sustainable green covery
• Focus COVID-19:
  Targeting coronavirus
  tests for pandemics
  antiviral drugs
  bioprocesses
  partnering events in corona times
• Artifical Intelligence in drug development,  diagnosis in cancer

• Data Management – collecting FAIR data – Findable, Accessible, Interoperable and Reusable